Low doses of 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor, stimulate angiogenesis by regulating expression of urokinase type plasminogen activator and matrix metalloprotease 2

Vascular Cell

Volumn 3, Issue , 2011, Pages

  Caldini, Riccardo ^a   Fanti, Elena ^a   Magnelli, Lucia ^a   Barletta, Emanuela ^a   Tanganelli, Elisabetta ^a   Zampieri, Michele ^b   Chevanne, Marta ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOBENZAMIDE; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; UROKINASE;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84858178110     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-3-12     Document Type: Article

References (33)

1. Angiogenesis in cancer and other diseases. Carmeliet P, Jain RK, Nature 2000 407 249 257 10.1038/35025220 11001068
2. Cancer invasion and metastasis: changing views. Duffy MJ, McGowan PM, Gallagher WM, J Pathol 2008 214 283 293 10.1002/path.2282 18095256 (Pubitemid 351212383)
3. Matrix metalloproteinases and angiogenesis. Rundhaug JE, J Cell Mol Med 2005 9 267 285 10.1111/j.1582-4934.2005.tb00355.x 15963249
4. FGF2-mediated upregulation of urokinase-type plasminogen activator expression requires a MAP-kinase dependent activation of poly(ADP-ribose) polymerase. Caldini R, Barletta E, Del Rosso M, Giovannelli L, Chevanne M, J Cell Physiol 2005 202 125 134 10.1002/jcp.20096 15389540 (Pubitemid 39603369)
5. Poly(ADP-ribosyl)ation, a molecular switch of transcription, shows an attractive relationship with urokinase expression. Chevanne M, Caldini R, Del Rosso M, Thromb Haemost 2005 93 220 227 15711736 (Pubitemid 40253725)
6. Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes. Krishnakumar R, Gamble MJ, Frizzell KM, Berrocal JG, Kininis M, Kraus WL, Science 2008 319 819 821 10.1126/science.1149250 18258916 (Pubitemid 351225873)
7. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM, Circulation 2002 106 927 932 10.1161/01.CIR.0000026393.47805.21 12186795 (Pubitemid 34925325)
8. Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation. Pacher P, Mabley JG, Soriano FG, Liaudet L, Komjáti K, Szabá C, Br J Pharmacol 2002 135 1347 1350 10.1038/sj.bjp.0704627 11906946 (Pubitemid 34270904)
9. PARP inhibitors for cancer therapy. Curtin NJ, Expert Rev Mol Med 2005 7 1 20 16842636
10. The potential of PARP inhibitors in genetic breast and ovarian cancers. Drew Y, Calvert H, Ann NY Acad Sci 2008 1138 136 145 10.1196/annals.1414.020 18837894
11. Chemopotentiation by PARP inhibitors in cancer therapy. Tentori L, Graziani G, Pharmacol Res 2005 52 25 33 10.1016/j.phrs.2005.02.010 15911331 (Pubitemid 40725597)
12. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Rajesh M, Mukhopadhyay P, Bátkai S, Godlewski G, Haská G, Liaudet L, Pacher P, Biochem Biophys Res Commun 2006 350 352 357 10.1016/j.bbrc.2006.09.049 17007818 (Pubitemid 44498642)
13. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Rajesh M, Mukhopadhyay P, Godlewski G, Bátkai S, Haská G, Liaudet L, Pacher P, Biochem Biophys Res Commun 2006 350 1056 1062 10.1016/j.bbrc.2006.09.160 17046715 (Pubitemid 44584200)
14. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Tentori L, Lacal PM, Muzi A, Dorio AS, Leonetti C, Scarsella M, Ruffini F, Xu W, Min W, Stoppacciaro A, Colarossi C, Wang ZQ, Zhang J, Graziani G, Eur J Cancer 2007 43 2124 2133 10.1016/j.ejca.2007.07.010 17714938 (Pubitemid 47380363)
15. Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses. Calabrese EJ, Crit Rev Toxicol 2005 35 463 582 10.1080/10408440591034502 16422392
16. Statins have biphasic effects on angiogenesis. Weis M, Heeschen C, Glassford AJ, Cooke JP, Circulation 2002 105 739 745 10.1161/hc0602.103393 11839631 (Pubitemid 34157379)
17. Safrole oxide induced human umbilical vein vascular endothelial cell differentiation into neuron-like cells by depressing the reactive oxygen species level at the low concentration. Su L, Zhao J, Zhao BX, Miao JY, Yin DL, Zhang SL, Biochim Biophys Acta 2006 1763 247 253 10.1016/j.bbamcr.2006.01.002 16473419
18. Differentiating and apoptotic dose-dependent effects in (-)-alpha-bisabolol-treated human endothelial cells. Magnelli L, Caldini R, Schiavone N, Suzuki H, Chevanne M, J Nat Prod 2010 73 523 526 10.1021/np9003933 20364847
19. Fibrinogen binding potentiates FGF-2 but not VEGF induced expression of u-PA, u-PAR, and PAI-1 in endothelial cells. Sahni A, Sahni SK, Simpson-Haidaris PJ, Francis CW, J Thromb Haemost 2004 2 1629 1636 10.1111/j.1538-7836.2004. 00845.x 15333041 (Pubitemid 40186181)
20. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Fibbi G, Caldini R, Chevanne M, Pucci M, Schiavone N, Morbidelli L, Parenti A, Granger HJ, Del Rosso M, Ziche M, Lab Invest 1998 78 1109 1119 9759655 (Pubitemid 28440827)
21. Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator. Tkachuk VA, Plekhanova OS, Parfyonova YV, Can J Physiol Pharmacol 2009 87 231 251 10.1139/Y08-113 19370078
22. Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Pyriochou A, Olah G, Deitch EA, Szabá C, Papapetropoulos A, Int J Mol Med 2008 22 113 118 18575783
23. Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells. Lacal PM, Tentori L, Muzi A, Ruffini F, Dorio AS, Xu W, Arcelli D, Zhang J, Graziani G, Int J Oncol 2009 34 861 872 19212692
24. IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly(ADP-ribose)polymerase. Beckert S, Farrahi F, Perveen Ghani Q, Aslam R, Scheuenstuhl H, Coerper S, Königsrainer A, Hunt TK, Hussain MZ, Biochem Biophys ResCommun 2006 341 67 72 10.1016/j.bbrc.2005.12.148 (Pubitemid 43117387)
25. Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line. Chevanne M, Zampieri M, Caldini R, Rizzo A, Ciccarone F, Catizone A, D'Angelo C, Guastafierro T, Biroccio A, Reale A, Zupi G, Caiafa P, J Cell Physiol 2010 222 401 410 10.1002/jcp.21964 19890834
26. Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. Rankin PW, Jacobson EL, Benjamin RC, Moss J, Jacobson MK, J Biol Chem 1989 264 4312 4317 2538435 (Pubitemid 19081328)
27. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Kleine H, Poreba E, Lesniewicz K, Hassa PO, Hottiger MO, Litchfield DW, Shilton BH, Lüscher B, Mol Cell 2008 32 57 69 10.1016/j.molcel.2008.08.009 18851833
28. Urokinase plasminogen activator system as a potential target for cancer therapy. Mekkawy AH, Morris DL, Pourgholami MH, Future Oncol 2009 5 1487 1499 10.2217/fon.09.108 19903074
29. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Morrison CJ, Butler GS, Rodríguez D, Overall CM, Curr Opin Cell Biol 2009 21 645 653 10.1016/j.ceb.2009.06.006 19616423
30. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. John A, Tuszynski G, Pathol Oncol Res 2001 7 14 23 10.1007/BF03032599 11349215 (Pubitemid 32591662)
31. Inhibition of matrix metalloproteinase-2 by PARP inhibitors. Nicolescu AC, Holt A, Kandasamy AD, Pacher P, Schulz R, Biochem Biophys Res Commun 2009 387 646 650 10.1016/j.bbrc.2009.07.080 19619515
32. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN, Bird RE, Hoythya M, Fuerst TR, French DL, et al. J Cell Physiol 1993 156 235 246 10.1002/jcp.1041560204 8344982 (Pubitemid 23244085)
33. JNK and PI3K differentially regulate MMP-2 and MT1-MMP mRNA and protein in response to actin cytoskeleton reorganization in endothelial cells. Ispanovic E, Haas TL, Am J Physiol Cell Physiol 2006 291 579 C588 10.1152/ajpcell.00300. 2005 16672691 (Pubitemid 44497584)